Clinical guidelines for the treatment of cancer-related anemia

Jim M. Koeller

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Defining clinical guidelines for the treatment of cancer-related anemia requires investigation into causes and characteristics of this malady, uses, benefits, and adverse effects of current treatments; and recognition of currently accepted guidelines set forth by the American College of Physicians and the American Association of Blood Banks. Anemia, the most common hematologic abnormality in patients with cancer, originates from a variety of causes, including occult blood loss, hypoproliferation, and hemolysis, and often involves more than one mechanism. Clinical manifestations include fatigue, dyspnea, tachycardia, dizziness, anorexia, and hypersensitivity to cold. Although the majority of cancer-related anemias are hypoproliferative, establishing their pathophysiology in individual patients is critical to effective treatment. Anemia usually, but not always, resolves with successful treatment of underlying disease. Symptomatic relief can be managed in accordance with established treatment guidelines.

Original languageEnglish (US)
Pages (from-to)156-169
Number of pages14
JournalPharmacotherapy
Volume18
Issue number1
StatePublished - Jan 1998

Fingerprint

Second Primary Neoplasms
Anemia
Guidelines
Occult Blood
Anorexia
Dizziness
Therapeutics
Hemolysis
Tachycardia
Dyspnea
Fatigue
Neoplasms
Physicians

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Clinical guidelines for the treatment of cancer-related anemia. / Koeller, Jim M.

In: Pharmacotherapy, Vol. 18, No. 1, 01.1998, p. 156-169.

Research output: Contribution to journalArticle

Koeller, JM 1998, 'Clinical guidelines for the treatment of cancer-related anemia', Pharmacotherapy, vol. 18, no. 1, pp. 156-169.
Koeller, Jim M. / Clinical guidelines for the treatment of cancer-related anemia. In: Pharmacotherapy. 1998 ; Vol. 18, No. 1. pp. 156-169.
@article{abe84365f6d040fbae58e7349141cd4d,
title = "Clinical guidelines for the treatment of cancer-related anemia",
abstract = "Defining clinical guidelines for the treatment of cancer-related anemia requires investigation into causes and characteristics of this malady, uses, benefits, and adverse effects of current treatments; and recognition of currently accepted guidelines set forth by the American College of Physicians and the American Association of Blood Banks. Anemia, the most common hematologic abnormality in patients with cancer, originates from a variety of causes, including occult blood loss, hypoproliferation, and hemolysis, and often involves more than one mechanism. Clinical manifestations include fatigue, dyspnea, tachycardia, dizziness, anorexia, and hypersensitivity to cold. Although the majority of cancer-related anemias are hypoproliferative, establishing their pathophysiology in individual patients is critical to effective treatment. Anemia usually, but not always, resolves with successful treatment of underlying disease. Symptomatic relief can be managed in accordance with established treatment guidelines.",
author = "Koeller, {Jim M.}",
year = "1998",
month = "1",
language = "English (US)",
volume = "18",
pages = "156--169",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical guidelines for the treatment of cancer-related anemia

AU - Koeller, Jim M.

PY - 1998/1

Y1 - 1998/1

N2 - Defining clinical guidelines for the treatment of cancer-related anemia requires investigation into causes and characteristics of this malady, uses, benefits, and adverse effects of current treatments; and recognition of currently accepted guidelines set forth by the American College of Physicians and the American Association of Blood Banks. Anemia, the most common hematologic abnormality in patients with cancer, originates from a variety of causes, including occult blood loss, hypoproliferation, and hemolysis, and often involves more than one mechanism. Clinical manifestations include fatigue, dyspnea, tachycardia, dizziness, anorexia, and hypersensitivity to cold. Although the majority of cancer-related anemias are hypoproliferative, establishing their pathophysiology in individual patients is critical to effective treatment. Anemia usually, but not always, resolves with successful treatment of underlying disease. Symptomatic relief can be managed in accordance with established treatment guidelines.

AB - Defining clinical guidelines for the treatment of cancer-related anemia requires investigation into causes and characteristics of this malady, uses, benefits, and adverse effects of current treatments; and recognition of currently accepted guidelines set forth by the American College of Physicians and the American Association of Blood Banks. Anemia, the most common hematologic abnormality in patients with cancer, originates from a variety of causes, including occult blood loss, hypoproliferation, and hemolysis, and often involves more than one mechanism. Clinical manifestations include fatigue, dyspnea, tachycardia, dizziness, anorexia, and hypersensitivity to cold. Although the majority of cancer-related anemias are hypoproliferative, establishing their pathophysiology in individual patients is critical to effective treatment. Anemia usually, but not always, resolves with successful treatment of underlying disease. Symptomatic relief can be managed in accordance with established treatment guidelines.

UR - http://www.scopus.com/inward/record.url?scp=0031964226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031964226&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 156

EP - 169

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1

ER -